PT
Pierrepont Therapeutics develops targeted therapeutic treatments for genetically defined Primary Mitochondrial Diseases. The company focuses on novel clinical stage treatments addressing specific patient populations with nuclear and mitochondrial DNA mutations. This focus addresses the unmet medical need in a complex disease category historically overlooked by the pharmaceutical industry.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- Pierrepont Therapeutics develops targeted therapeutic treatments for genetically defined Primary Mitochondrial Diseases. The company focuses on novel clinical stage treatments addressing specific patient populations with nuclear and mitochondrial DNA mutations. This focus addresses the unmet medical need in a complex disease category historically overlooked by the pharmaceutical industry.